Category Generic Drugs

Intellipharmaceutics Announces Appointment of New Chief Financial Officer [Kuwait News Agency]

Nov20

Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has appointed Domenic Della Penna as its new Chief Financial Officer (CFO) effective November 24, 2014.Mr. Della Penna brings considerable expertise and industry experience to the Company. […]

Ackman’s Pershing Square Withdraws Call For Allergan Special Shareholder Meeting

Nov19

WASHINGTON (dpa-AFX) – Activist investor William Ackman’s hedge fund Pershing Square Capital Management LP has in a regulatory filing on Tuesday formally withdrawn its request for a special shareholder meeting of Botox maker Allergan, Inc. (AGN) following a windfall he made despite losing out on the deal to acquire it. The meeting was scheduled for […]

AUXILIUM PHARMACEUTICALS INC FILES (8-K) Disclosing Other Events

Nov19

Item 8.01 Other EventsLitigation UpdateAs previously disclosed, Auxilium Pharmaceuticals, Inc. ("Auxilium" or the"Company") and FCB I Holdings Inc. ("FCB") have been litigating various matterswith Upsher-Smith Laboratories, Inc. ("Upsher-Smith") related to Upsher-Smith’sfiling of Paragraph IV certifications in connection with a 505(b)(2) New DrugApplication (the "505(b)(2) NDA") and an Abbreviated New Drug Application, ineach case, using Testim […]

Advent International and Avista Capital Partners to Acquire Kremers Urban Pharmaceuticals from UCB

Nov19

By a News Reporter-Staff News Editor at Biotech Week Advent International and Avista Capital Partners announced that they have signed an agreement to acquire Kremers Urban Pharmaceuticals Inc. (“KU”), the U.S. specialty generic pharmaceuticals subsidiary of global biopharmaceuticals company UCB, S.A. (Euronext: UCB), for $1.525 billion. The transaction, subject to regulatory approval and other customary […]

Investigators from Institute for Public Health Zero in on Health Services Research (Distribution and trends in outpatient utilization of generic…

Nov19

Investigators from Institute for Public Health Zero in on Health Services Research (Distribution and trends in outpatient utilization of generic versus brand name psychopharmaceuticals during a ten-year period in Croatia)By a News Reporter-Staff News Editor at Biotech Week Current study results on Health and Medicine have been published. According to news reporting originating in Zagreb, […]

Arrowhead Files For Regulatory Permission To Begin Phase 1 Trial Of RNAi; TapImmune Announces Phase II Clinical Trials with VGTI Florida

Nov19

Below is a look at some of the headlines for companies that made news in the healthcare sector on November 18, 2014.{nfg}Arrowhead Research Corporation (NasdaqGS: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it recently filed an application for approval to begin a Phase 1 clinical trial of its RNAi-based therapeutic candidate, […]

Biogen Idec and Samsung Bioepis Announce Agreement to Market Anti-TNF Biosimilar Product Candidates in Europe

Dec30

By a News Reporter-Staff News Editor at Pharma Business Week Biogen Idec (NASDAQ: BIIB) and Samsung Bioepis announced that through their joint venture, Biogen Idec has exercised its right to enter into an agreement to commercialize anti-TNF biosimilar product candidates in Europe, including biosimilars for widely used therapies to treat conditions such as rheumatoid arthritis […]

Inhalation & Nasal Spray Generic Drugs 2013

Dec30

By a News Reporter-Staff News Editor at Pharma Business Week Research and Markets has announced the addition of the “Inhalation & Nasal Spray Generic Drugs 2013″ report to their offering (see also Research and Markets).Around three quarters of the US$36.4 billion respiratory prescription drugs market comprises drugs that are delivered using inhalation or nasal spray […]

Decision Resources: Biosimilars for Rheumatoid Arthritis to Experience Rapid Uptake in Public Sectors of Brazil and Mexico [Professional Services Close

Dec30

Decision Resources, a research and advisory firm for pharmaceutical and healthcare issues, finds that biosimilars will be quickly acquired and used in public health institutions in Brazil and Mexico in the treatment of patients with rheumatoid arthritis (RA).In a release, the firm noted:Public formularies, treatment guidelines, public tender acquisition processes and prescriptions all reference only […]

FTC to Hold Rescheduled Workshop on February 4 Examining the Competitive Impacts of State Regulations and Naming Conventions Concerning Follow-on…

Dec30

FTC to Hold Rescheduled Workshop on February 4 Examining the Competitive Impacts of State Regulations and Naming Conventions Concerning Follow-on BiologicsWASHINGTON, Dec. 30 The Federal Trade Commission issued the following news release:The Federal Trade Commission announced its one-day public workshop on competition and follow-on biologics has been rescheduled for Feb. 4, 2014. The workshop will […]